Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.21.2
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Revenue from contract with customer $ 9,000     $ 7,000     $ 45,000 $ 31,000  
Grant and other revenue 87,266     261,616     436,500 664,848  
Revenues, Total 96,382     268,389     481,165 695,762  
Research and development expenses 1,048,786     1,377,998     3,769,596 3,659,046  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,451,309     1,773,532     5,077,058 4,894,778  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 18,066     15,402     55,672 51,501  
Loss from operations (2,421,779) [3]     (2,898,625) [3]     (8,421,161) [3] (7,910,611)  
Other expense (4) [4] (14)     (713)          
Income tax expense (16,043)     0     (16,043) 0  
Net loss (2,437,836) $ (2,674,040) $ (2,966,892) (2,899,338) $ (2,325,619) $ (2,673,608) (8,078,768) (7,898,566)  
Total assets, net of depreciation and amortization 8,959,546           8,959,546   $ 7,758,018
Capital expenditures 18,042     120,810     20,749 129,216  
Cost of revenue 0     82     0 1,048  
Other income (4) (14)     (713)     358,436 [4] 12,045 [4]  
UNITED STATES                  
Total assets, net of depreciation and amortization 8,742,603     5,879,053     8,742,603 5,879,053  
Non-US [Member]                  
Total assets, net of depreciation and amortization 216,943     116,782     216,943 116,782  
License [Member]                  
Revenue from contract with customer 9,116     4,726     44,665 4,726  
Royalty [Member]                  
Revenue from contract with customer 0     2,047     0 26,188  
Diagnostics Segment [Member]                  
Grant and other revenue 87,266     106,729     436,500 381,103  
Revenues, Total 96,382     113,502     481,165 412,017  
Research and development expenses 906,677     1,251,383     3,359,190 3,402,160  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0     0     0 0  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 6,040     4,027     18,121 4,027  
Loss from operations (816,335) [3]     (1,268,605) [3]     (2,896,146) [3] (2,995,218)  
Other expense (4) [4] 0     0          
Income tax expense (5,763)           (5,763)    
Net loss (822,098)     (1,141,990)     (2,901,909) (2,995,218)  
Capital expenditures 0     120,810     0 120,810  
Cost of revenue       82       1,048  
Other income (4) [4]             0 0  
Diagnostics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 185,205     1,000     185,205 1,000  
Diagnostics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 216,353     116,782     216,353 116,782  
Diagnostics Segment [Member] | License [Member]                  
Revenue from contract with customer 9,116     4,726     44,665 4,726  
Diagnostics Segment [Member] | Royalty [Member]                  
Revenue from contract with customer       2,047       26,188  
Therapeutics Segment [Member]                  
Grant and other revenue 0     154,887     0 283,745  
Revenues, Total 0     154,887     0 283,745  
Research and development expenses 142,109     126,615     410,406 256,886  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 744     0     3,623 (550)  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 0     0     0 0  
Loss from operations (142,853) [3]     28,272 [3]     (414,029) [3] 27,409  
Other expense (4) [4] 0     0          
Income tax expense (824)           (824)    
Net loss (143,677)     28,272     (414,853) 27,409  
Capital expenditures 0     0     0 0  
Cost of revenue       0       0  
Other income (4) [4]             0 0  
Therapeutics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 0     38,320     0 38,320  
Therapeutics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 0     0     0 0  
Therapeutics Segment [Member] | License [Member]                  
Revenue from contract with customer 0     0     0 0  
Therapeutics Segment [Member] | Royalty [Member]                  
Revenue from contract with customer       0       0  
Corporate Segment [Member]                  
Grant and other revenue 0     0     0 0  
Revenues, Total 0     0     0 0  
Research and development expenses 0     0     0 0  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,450,565     1,773,532     5,073,435 4,895,328  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 12,026     11,375     37,551 47,474  
Loss from operations (1,462,591) [3]     (1,784,907) [3]     (5,110,986) [3] (4,942,802)  
Other expense (4) [4] (14)     (713)          
Income tax expense (9,457)           (9,457)    
Net loss (1,472,062)     (1,785,620)     (4,762,007) (4,930,757)  
Capital expenditures 18,042     0     20,749 8,406  
Cost of revenue       0       0  
Other income (4) [4]             358,436 12,045  
Corporate Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 8,557,398     5,839,733     8,557,398 5,839,733  
Corporate Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 590     0     590 0  
Corporate Segment [Member] | License [Member]                  
Revenue from contract with customer $ 0     0     $ 0 0  
Corporate Segment [Member] | Royalty [Member]                  
Revenue from contract with customer       $ 0       $ 0  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($18,066 and $15,402 for the three-month periods ended September 30, 2021 and 2020, and $55,672 and $51,501 for the nine-month periods ended September 30, 2021 and 2020, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.